PMID- 24916185
OWN - NLM
STAT- MEDLINE
DCOM- 20150109
LR  - 20180507
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 210
IP  - 11
DP  - 2014 Dec 1
TI  - Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in 
      intravenous immunoglobulin as a potential therapeutic against emerging influenza 
      viruses.
PG  - 1811-22
LID - 10.1093/infdis/jiu334 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is a purified pool of human 
      antibodies from thousands of donors that is used to prevent or treat primary 
      immune deficiency, several infectious diseases, and autoimmune diseases. The 
      antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against 
      heterologous influenza strains may be present in IVIG preparations. METHODS: We 
      tested 8 IVIG preparations prior to the 2009 H1N1 swine-origin influenza pandemic 
      and 10 IVIG preparations made after 2010 for their ability to mediate 
      influenza-specific ADCC. RESULTS: ADCC mediating antibodies to A(H1N1)pdm09 
      hemagglutinin (HA) and neuraminidase (NA) were detected in IVIG preparations 
      prior to the 2009-H1N1 pandemic. The HA-specific ADCC targeted both the HA1 and 
      HA2 regions of A(H1N1)pdm09 HA and was capable of recognizing a broad range of HA 
      proteins including those from recent avian influenza strains A(H5N1) and A(H7N9). 
      The low but detectable ADCC recognition of A(H7N9) was likely due to rare 
      individuals in the population contributing cross-reactive antibodies to IVIG. 
      CONCLUSIONS: IVIG preparations contain broadly cross-reactive ADCC mediating 
      antibodies. IVIG may provide at least some level of protection for individuals at 
      high risk of severe influenza disease, especially during influenza pandemics 
      prior to the development of effective vaccines.
CI  - (c) The Author 2014. Published by Oxford University Press on behalf of the 
      Infectious Diseases Society of America. All rights reserved. For Permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Jegaskanda, Sinthujan
AU  - Jegaskanda S
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne.
FAU - Vandenberg, Kirsten
AU  - Vandenberg K
AD  - BioCSL Ltd, Parkville, Victoria.
FAU - Laurie, Karen L
AU  - Laurie KL
AD  - WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, North 
      Melbourne, Victoria, Australia.
FAU - Loh, Liyen
AU  - Loh L
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne.
FAU - Kramski, Marit
AU  - Kramski M
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne.
FAU - Winnall, Wendy R
AU  - Winnall WR
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne.
FAU - Kedzierska, Katherine
AU  - Kedzierska K
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne.
FAU - Rockman, Steven
AU  - Rockman S
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne BioCSL Ltd, Parkville, Victoria.
FAU - Kent, Stephen J
AU  - Kent SJ
AD  - Department of Microbiology and Immunology, at the Peter Doherty Institute for 
      Infection and Immunity, University of Melbourne.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140610
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antibodies, Viral)
RN  - 0 (Hemagglutinin Glycoproteins, Influenza Virus)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
CIN - EBioMedicine. 2017 May;19:10-11. PMID: 28431940
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Viral/blood/*immunology
MH  - Antibody-Dependent Cell Cytotoxicity/*immunology
MH  - Cross Reactions/*immunology
MH  - Female
MH  - Hemagglutination Tests
MH  - Hemagglutinin Glycoproteins, Influenza Virus/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Influenza A Virus, H1N1 Subtype/*immunology
MH  - Influenza A Virus, H7N9 Subtype/immunology
MH  - Influenza, Human/*immunology/*therapy
MH  - Killer Cells, Natural/immunology
MH  - Male
MH  - Middle Aged
MH  - Young Adult
OTO - NOTNLM
OT  - ADCC
OT  - IVIG
OT  - NK cells
OT  - influenza
OT  - swine-origin influenza virus
EDAT- 2014/06/12 06:00
MHDA- 2015/01/13 06:00
CRDT- 2014/06/12 06:00
PHST- 2014/06/12 06:00 [entrez]
PHST- 2014/06/12 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
AID - jiu334 [pii]
AID - 10.1093/infdis/jiu334 [doi]
PST - ppublish
SO  - J Infect Dis. 2014 Dec 1;210(11):1811-22. doi: 10.1093/infdis/jiu334. Epub 2014 
      Jun 10.